Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial

Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.